Kanso Diagnostics

Company Overview

Snapshot

Founded in March 2022 by Roy Rabinowitz and Omer Stoller, Kanso Diagnostics operates with 1–10 employees. The company has raised $1.6M across four funding rounds, with Peregrine Ventures participating as a lead investor in one of the rounds.

Business overview

Kanso Diagnostics is developing a molecular testing platform for the diagnosis of bacterial and viral infections, aiming to revolutionize contemporary diagnostics. Their solution facilitates at-home medical testing, emphasizing accessibility and ease of use. The proprietary technology accurately detects multiple pathogens and genetic biomarkers from a single sample, significantly reducing diagnosis time from days to minutes with PCR-grade accuracy. The company operates within the Health Tech & Life Sciences sector, focusing on diagnostics devices, and serves markets including healthcare providers, patients, and the biotechnology industry.

Strategic signal

Kanso Diagnostics has garnered attention for its innovative approach to rapid diagnostic testing, as highlighted by news coverage in January 2025. Articles from TheMarker and Haaretz, titled 'Faster, Simpler, Better,' underscore the company's potential to transform the diagnostics landscape. This indicates strong market validation and growing interest in Kanso's technology, positioning it as a key player in advancing accessible and efficient medical diagnostics.

Company Intelligence Q&A

What is Kanso Diagnostics' core technology?

Kanso Diagnostics develops a proprietary molecular testing platform designed for the rapid and accurate diagnosis of bacterial and viral infections. This technology can detect multiple pathogens and genetic biomarkers from a single sample, providing PCR-grade accuracy for at-home testing.

When was Kanso Diagnostics founded and by whom?

Kanso Diagnostics was founded in March 2022 by co-founders Roy Rabinowitz, who serves as CEO, and Omer Stoller, the CTO.

Which investors have participated in Kanso Diagnostics' funding rounds?

Kanso Diagnostics has received funding from investors including Peregrine Ventures. Peregrine Ventures led a seed round in June 2023.

What is the primary market focus for Kanso Diagnostics' products?

Kanso Diagnostics focuses on the Health Tech & Life Sciences sector, specifically targeting the diagnostics devices market. Their solutions are designed for healthcare providers, patients, and the broader biotechnology industry, aiming to enable accessible and rapid at-home testing.